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Summary Decision theory was used to calculate the optimum treatment of microscopic squamous cervical
cancer using probabilities obtained from an exhaustive literature review and a range of plausible value
estimates. This showed that if there is no vascular involvement, survival is maximised by conservative
treatment if tumour invasion is less than 3 mm while treatment by radical surgery results in maximal survival
rates if the tumour invasion is over 3 mm. Radical surgery also maximises survival for smaller lesions where
lymph channel involvement is present, especially if a surgical mortality at the lower end of the reported range
is assumed. Refinement of our analysis to include an assessment of patient values showed that these
conclusions are still valid regardless of the patient's relative preference for death from surgery or death from
cancer. However, the wish to preserve fertility sharply reduces the overall net benefit of surgery. Conservative
treatment becomes the preferred option for all microinvasive lesions even for patients who are prepared to
trade-off a small (e.g. 2%) risk of death in order to retain their fertility.
The management of early microinvasive cervical cancer has
been intensely debated for many years. There are advocates
of radical therapy if the depth of invasion of a squamous
cervical carcinoma is great than 1 mm (Nelson et al., 1975;
Averette et al., 1976) while others (Christopherson, 1976;
Przybora, 1965; Ruch et al., 1976) occasionally employ con-
servative methods even if the degree of penetration is 5 mm.
In this paper we examine all the available literature from the
last 20 years and use decision analysis to compare radical
and conservative surgery. The issue is presented as a clinical
problem with the diagnosis made from a cervical cone biopsy
in which all margins are well clear of tumour. The model
uses all aspects of decision analysis and provides an example
of how it can be used to study a clinical problem. Although
there may be difficulty in deciding whether or not invasion is
present, this article begins with the premise that the diagnosis
of microscopic invasion has been made.
Subjects and methods
A decision tree was constructed to answer the question 'what
is the best treatment for uncomplicated microinvasive
squamous cancers of the cervix?' Survival, fertility and the
mode of death are considered to be the most important end
points.
Constructing the decision tree
We start from the premise that the diagnosis has been made
from the histological examination of a cone-biopsy and that
excision is complete leaving a substantial margin of normal
tissue. There are 5 possible 'treatment choices':- cone biopsy,
hysterectomy, hysterectomy with pelvic lymphadenectomy,
radiotherapy or a combination of surgery and radiotherapy.
If we construct a decision tree with five initial branches it
rapidly gets cluttered and complex, so it will be pruned at
this stage. Unless the patient is infirm there are likely to be
few supporters of radiotherapy for the first line treatment of
microinvasive cancer of the cervix. This leaves cone biopsy,
hysterectomy or radical surgery. In the absence of other
pelvic or menstrual diseases hysterectomy after a cone biopsy
has a greater morbidity than no further treatment. It is
difficult to see how hysterectomy can offer a meaningful
survival advantage if the tumour is widely and adequately
excised as tumour recurrence is dependent on metastasis
rather than on seedlings in the uterus. Hysterectomy, though
sometimes advocated, has a poor axiomatic base in this
situation and it will be pruned from the decision tree. The
treatment options therefore depend upon a decision between
no further therapy (apart from follow-up) versus radical
surgery.
The decision tree is shown in Figure I and the probability
of surviving the disease can be computed for each branch to
determine the preferred treatment.
Estimating the probabilities
The survival rates for the various stages of the disease
depend on the respective probabilities of spread which, in
turn, reflect the probabilities of developing recurrence of the
disease. This probability was estimated from a detailed
review of 85 papers from the English literature over the past
22 years. These authors analysed their results by depth of
invasion from the basement membrane and followed up their
patients for at least 5 years. Fifty-five of these papers give
probabilistic information on the risk of spread but a further
18 of these were excluded because the depth of invasion was
not specifically measured, or invasion to more than 5 mm
was included in a single category. This left 34 papers (Table
I) which specified invasion to a depth of 5 mm or less (3130
patients). Twenty-four papers included information on the
frequency of lymph node metastases according to depth of
invasion. Operative mortality was obtained from 13 studies
reviewed by Shingleton and Orr (1983).
Threshold analysis
Decision analysis revealed that the management of women
with microinvasive cancer involving stromal vessels and
penetrating the basement membrane up to 1 mm depends
upon the precise operative mortality of radical surgery.
Therefore, the cut off point of when to operate and when not
to operate was calculated by making the survival score from
cone biopsy equal the score from radical surgery. In other
words, we calculated the operative mortality associated with
identical survival rates for both treatment options for women
with very early microinvasive cancer involving stromal
vessels. When the operative mortality is greater than this
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threshold then cone biopsy is the treatment associated with
maximum survival for this condition.
Utility analysis
Since overall survival is not the sole factor to be considered
in this decision, we extended the analysis to allow for trade-
offs between peri-operative mortality and delayed death from
cancer and the potential impact of infertility. For practical
reasons the utility assessment exercise was limited to a






















20 students, 30 administrators and 31 medical secretaries)
were asked to imagine that they were patients afflicted with
microinvasive cancer of the cervix, and to answer some
hypothetical questions. They were asked to imagine them-
selves as a 50 year old woman with a completed family and
later they were also asked to imagine themselves in the
situation of a young woman (aged 24), engaged to be mar-
ried, and wishing to have a family. Of the available methods
of assessing utility (Hershey et al., 1985; von Neumann &
Morgenstern, 1947; Weinstein, 1986) we chose the multiple
gamble technique, using certainty equivalence techniques
(Hershey et al., 1985), based on the Von Neumann-
Morgenstern methodology (von Neumann & Morgenstern,
1947). Three workers acting independently collected the data.
Sensitivity analysis
Sensitivity analysis was performed to assess the influence of
infertility and mode of death on the final decision. We con-
sidered cases where the subject was indifferent between the
two forms of death, where the subject ranked cancer death
slightly higher than surgical death (representing the mean in
our study) and where the subject rated surgical death twice as
undesirable as cancer death. As far as infertility is concerned
we included the median score and a range of values defined
by the multiple gamble technique. The values ranged from
.25 (the lowest score) to 1.00 (indifferent between fertility/
infertility). Although this defines the limits or our sensitivity
analysis in clinical practice, treatment must be tailored to
each individual patient.
Figure 1 Decision tree for the management of microinvasive
cancer of the cervix.
Table I Articles giving prognostic information on microinvasive squamous cervical
cancer
Number with
Number Maximum positive Deathfrom Years of
Author ofcases depth lymph nodes recurrence follow-up
Ullery 28 4 mm 0 0 5
Margulis 27 5 mm NS 0 1 -10
Thompson 49 5 mm 0 0 NS
Mussey 91 5 mm 1 2 5 +
Tarkington 12 5 mm 0 0 NS
Foushee 44 5mm 1 0 5 +
Ng 66 5 mm 0 0 1-21
Boutselis 45 5 mm 0 0 5
Creasman 98 5 mm 1 0 5-26
Rubio 210 5 mm NS 6 NS
Roche 30 5mm 0 0 NS
Ruch 115 5 mm 1 2 5 +
Averette 162 1 mm 0 0 NS
Bohn 69 3 mm 4 2 5
Lehman 51 5 mm 0 0 NS
Christopherson 111 5 mm 0 2 5-10
Re 58 3mm 0 0 NS
Chitale 22 5 mm 0 NS NS
Seski 54 3 mm 0 0 5-10
Hamberger 41 3 mm 0 0 NS
Wilkinson 29 1 mm 0 NS 1-17
Popkin 254 5 mm 0 2 5-20
Sedlis 133 5 mm 0 2 2-5
Krishna 30 5mm 0 NS NS
Iversen 122 5 mm 0 3 5-25
Yajima 188 3 mm 0 2 5
Averette 178 1 mm 0 0 NS
Taki 193 3 mm 0 1 NS
Hasumi 135 5 mm 5 NS NS
Bocci 32 3 mm 0 0 54
Van Nagell 177 5mm 3 2 2-14
La Vecchia 37 3mm 0 0 NS
Creasman 114 5 mm 3 0 NS
Simon 125 5mm 1 0 1-10
NS - not stated.
q
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Results
Theprognosis ofvarious microinvasive cervical cancers
From analysis of the literature the possibility that a lesion,
that was reported as completely excised, would have metas-
tasised beyond the limits of an apparently adequate cone
biopsy is found on Table II. In the absence of treatment the
probability of death if the tumour has spread beyond the
cervix must be assumed to be 100%. The cure obtained by
radical surgery in the presence of 'spread' is approximately
50%. This value is obtained from the survival rates of
patients with microinvasive cervical cancer who have positive
nodes identified following lymphadenectomy and radical
surgery (Averette et al., 1976; Christopherson et al., 1976;
Ruch et al., 1976; Boutselis et al., 1971; Wilkinson &
Komorowski, 1978; Yajima & Noda, 1979; Krishna et al.,
1979; Mussey, et al., 1969; Ng & Reagan, 1969; Sedlis et al.,
1979; Simon et al., 1986; Taki et al., 1979; Tarkington et al.,
1969; Van Nagell et al., 1983; Bohn et al., 1976; Chitale et
al., 1977; Creasman et al., 1985; Hasumi et al., 1980; Leman
et al., 1976; Margulis et al., 1966; Thompson, 1968; Roche &
Norris, 1975; Ullery et al., 1965; Hsu et al., 1972; Lohe,
1978; Peel et al., in press) and this is slightly better than the
survival figure of 30% for patients with stage 1B cervical
cancer who are subsequently found to have positive nodes.
An operative mortality of 0.5% (5 per 1,000) was cal-
culated (geometric mean) from the review of 13 recent studies
by Shingleton and Orr, 1983. As published reports may not
reflect current achievable results and as results have been
improving within the last decade, we have based our calcula-
tions both on the above figure and also on a revised pro-
bability estimate of surgical mortality of 0.25%.
Determining which treatment optimises survival
The results of decision analysis conducted purely to deter-
mine the method of management which maximises the
chances of survival are shown in Figures 2 and 3. It is clear
Table II Risk of distant spread (p) at the time of presentation
according to the depth ofinvasion
Depth of No lymph channel Lymph channel
invasion involvement involvement
< I mm 0% 0.7% (n =207)
0-3 mm 0% (n = 400) 2% (n = 238)
3 +-5mm 2% (n =207) 10% (n = 102)
Cone
The lowest mortality
is this side of
the lines
Maximalt
















Figure 3 The expected mortality from radical surgery relative to
cone biopsy (i.e. no further treatment) assuming q (probability of
death from surgery) = 0.25% (dotted line) and 0.5% (continuous
line).
from this that if an operative mortality of 0.5% is assumed,
then conservative treatment is the safest option until the
probability of spread has increased to 1%, whereas with an
operative mortality of0.25%, surgical treatment is preferable
at a lower (+%) risk of spread. The chance of pelvic lymph
node involvement for all lesions with more than 3 mm of
invasion is greater than 2% and appears to be over 10% if
there is vascular channel involvement in the cervical stroma.
Thus, in general terms, operative treatment should be recom-
mended for all cancers of the cervix, with invasion to more
than 3 mm, even if the higher surgical mortality is assumed
provided that maximising chances of survival is the sole
objective.
In the absence of vascular or lymphatic involvement, con-
servative treatment is safer for lesions within 3 mm of the

















Figure 2 Relating the risk of cancer spread to mortality (y axis).
The mortality from cone biopsy (i.e. no further treatment) equals
the risk of spread (P) (i.e. y = p} and the mortality from radical
surgery equals the operative mortality (q) plus the risk of spread
(P) times the surgical failure rate (1-r) (i.e. y = q+ p (l-r)).
Figure 4 Decision tree incorporating subjects utilities; P = -
probability of distant spread; q = surgical mortality rate; r = the
chance surgery will cure distant spread; U(I) = utility of infer-
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This is because the chance that the lesions have metastasised
is less than 0.5% in these cases. However if lymph or blood
vascular channels are involved, radical therapy will maximise
chances of survival even when the depth of invasion is less
than 3 mm, provided that the operative mortality is low
(0.25%). This does not apply when the invasion is less than
1 mm if the unit has a higher operative mortality because
these lesions have a 0.7% chance of lymph-node spread (only
half will be cured by lymphadenectomy and the operative
mortality is 0.5%). Threshold analysis can be used to deter-
mine which units should offer radical surgery to a woman
with stromal lymphatic or vascular involvement. For early
lesions (<1 mm invasion) the probability of spread is 0.7%.
The mortality associated with radical surgery is the operative
mortality (q) plus the probability dying from cancer despite
surgery (pr); (i.e. q +0.35%). When 0.7% = q + 0.35% the
survival of such patients is identical irrespective of the
therapy chosen. Therefore when the operative mortality rate
is 0.35% (q = 0.7%-0.35%) both treatment options are
associated with identical survival rates. Below this threshold
radical surgery optimises survival but if the mortality exceeds
this, cone biopsy (i.e. no further treatment) will achieve the
maximum survival.
Utility analysis ignoring infertility
Analysis ignoring infertility is appropriate for patients who
have completed their family and do not want more children.
Sixty per cent of subjects indicated that they would prefer
cancer death to surgical death, while 40% had the reverse
opinion. On average, subjects indicated that they regarded
surgical death to be worse than death from cancer two years
later with relative utilities of 0.161 and 0.106 respectively. At
an operative mortality of 0.5%, incorporating these utility
scores into the decision tree will obviously favour conser-
vative therapy slightly for most patients. If we assume an
operative mortality of 0.25%, then surgery is no longer the
optimum therapy when the chance of spread is 0.5%. At a
chance of spread of 1% or more, however, surgery is still the
preferred option regardless of the preferred mode of death
(Table III). The practical importance of these findings is that
although we are now biased very slightly away from surgery,
(if we ignore infertility as an outcome) these utilities have
very little impact on the final decision. Radical surgery re-
mains the best option when the depth of invasion exceeds
3 mm and when vascular channels are involved in more
superficial lesions (1-3 mm invasion).
Utility analysis taking infertility into account
A median utility of 0.998 was obtained by the multiple
gamble technique for infertility in a young girl about to be
married and desirous of having children. This implies that
our subjects would accept 1 in 500 risk of cancer death to
avoid hysterectomy. One subject would accept a risk to her
life of 1 in 4 to avoid a hysterectomy, 2 would accept a risk
of 1 in 10 and 10 women (9%) would accept a risk of 1 in 50.
Folding back along the decision tree (Figure 1) these scores
Table In Sensitivity analysis ofthe expected utility ofradical surgery
(U(surg)) relative to conebiopsy{U(cone)) fordifferentprobabilities of
cancer spread (P) and different relative utilities for preferred mode of
death U(CD) & U(SD) for a woman who has completed her family
(U(I) = 1.00) and assuming q (probability of death from surgery)
= 0.25% and the surgical cure rate is 50%
Relative utility ofcancer andsurgical death (U(CD)Iu(sD))
0 0 0.161a 0.125 0.25
0.125 0 0.106a 0 0
Surgical
U(surg) death




0.25% 0.9991 0.9987 0.9989 0.9986 0.9985
0.5% 1.0003 1.0000 0.9998 0.9996 0.9993
0.7% 1.0013 1.0010 1.0007 1.0006 1.0001
I% 1.0028 1.0025 1.0020 1.0018 1.0012
2% 1.0081 1.0078 1.0063 1.0064 1.0052
10% 1.0532 1.0529 1.0458 1.0453 1.0379
Note that when (Ucone) > U(surg), cone biopsy is best treatment
option.Alsonotethatthevalueshardlychangeevenifawomanchanges
from a strong preference for surgical death to cancer death. For
example, iftherisk ofspread is 0.25%, conservative therapy is optimal
for all patients, while at a 1% risk ofspread surgery is optimal for all
patients. aMeanvalues ofcancerdeath and surgicaldeathfrom ranking
scales.
favour conservative therapy (Table IV). Sensitivity analysis
(using a range of utilities) shows that when we use a value of
0.98 (implying indifference between a 1 in 50 risk of death
from cancer to avoid the certainty of infertility), conservative
therapy becomes the preferred treatment option for microin-
vasive lesions not involving vessels but invading 3 mm below
the basement membrane (Table IV).
Discussion
Gynaecologists often think that conservative therapy should
be superseded by radical surgery when the probability of
spread exceeds the operative mortality. Our decision analysis
shows that, even from the point of view of maximising
survival, this is erroneous because the failure rate of surgery
must be taken into account. When depth of invasion is less
than 3 mm with no vascular involvement, the risk of spread
is so low, that surgery is not warranted. Where invasion
exceeds 5 mm or where it exceeds 3 mm with vascular
involvement the risk of spread increases exponentially and
there must be very few patients for whom conservative
therapy is appropriate. Between these two extremes the best
treatment depends on the desire to retain fertility.
A large number ofobservational studies have been directed
at determining the probabilities required for this analysis.
The risk of spread associated with different histological
criteria is central to the analysis. Only a small subset of the
large number ofpapers that have addressed this issue contain
Table IV Sensitivity analysis of expected utility of radical surgery relative to cone biopsy
Utility ofInfertility (0-implies life is not worth living)
Risk of (1.00-implies infertile life is as
spread desirable asfertile life
P .25 .50 .75 .95 .98 1.00
0.25% 0.250 0.499 0.749 0.952 0.980 0.999
0.5% 0.250 0.500 0.751 0.952 0.980 1.000
0.7% 0.251 0.501 0.751 0.951 0.981 1.001a (invasion< 1 mm + lymphatics)
2% 0.253 0.505 0.756 0.957 0.986 1.006a (invasion<3 mm + lymphatics)
5% 0.255 0.512 0.763 0.970 l.001a 1.020a
10% 0.268 0.526 0.785 0.992 1.023a 1.045a (3 mm<invasion< 5 mm + lymphatics)
aIfthe ratio oftheexpected utility ofsurgery tocone biopsyis greater thenonesurgeryis thepreferredoption. Note:
Based onmeanutility scoresforcancerdeath and surgical death(0.161 and0.106)andprobability (q)ofsurgicaldeath
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information on lymph node pathology and there is no unifor-
mity in reporting depth of invasion or follow-up period.
Secondly although the operative mortality of radical surgery
has been reported in many studies and quoted as 0.5% the
more recent reports tend to show lower mortality figures
(approaching 0.25%). As no unit will ever do sufficient
radical hysterectomies in a short period of time their precise
operative mortality will never be known. Thirdly surgical
failure rates of 70% are usually quoted in the presence of
lymphatic spread. The references which we have quoted,
however, show that the chances of cure are better when
spread is less extensive. We have therefore used an estimate
that half of patients with spread will be cured by radical
therapy usually consisting of extended hysterectomy (Wer-
theim's) and pelvic lymphadenectomy. Although these are the
best data available their accuracy will limit the confidence
intervals of any decision analysis.
We have also left aside the morbidity of surgery, which
may be considerable when ureteric dissection and lym-
phadenectomy is carried out. Fistulae, for example, occur in
nearly 3% of cases (Shingleton & Orr, 1983) but surgical
complications temporarily reduce life quality and play a
trivial part in the final equation dominated by survival and
fertility. The final limitation of decision analysis involves our
ability to measure the extent to which patients would sacrifice
the chances of cure in order to avoid operative death (or vice
versa), or to avoid infertility. When obtaining utilities for
outcomes the ranking scale is conceptually easier for subjects
to use (Gafni & Torrance, 1984), but this does not produce
numerically accurate and definitive answers (Thornton,
1990). However our findings are confirmed by other reports
(McNeil et al., 1981; 1982) suggesting that most people prefer
delayed death to immediate surgical death. The utility values
obtained from the standard gamble method lie close to the
range of informed human choice (Torrance, 1986) but there
are still several reasons why findings may not accurately
reflect subjects' true preferences:- (i) there is a tendency for
individuals to exhibit pure risk aversion or a reluctance to
gamble per se, (ii) practical behaviour limitations of utility
assessment (Bombardier, 1982) and (iii) the difficulty subjects
have in interpreting very small probabilities (Torrance, 1986).
It is difficult to eliminate these errors. Furthermore it would
be wrong to extrapolate treatment for individuals from
population means as the optimum treatment of the disease
for the mean population may not be the preferred treatment
for that patient. In order to tailor the best treatment to suit
each patient, sensitivity analysis was carried out to determine
the effect of a range of possible utilities for cancer death,
surgical death and infertility on choice of therapy. Table III
shows a sensitivity analysis in which we ignore infertility, as
one would when treating a patient who had 'completed her
family'. When subjects are indifferent between cancer and
surgical death, the results are the same as those where we
wished simply to maximise chances of survival. However
even if patients express a strong wish to avoid either a
surgical or cancer death the optimum treatment is
unchanged. This shows that our conclusions are very robust
to changes in an individual's preference for surgical and
cancer death and implies that patients preferences on their
method of death are unlikely to change the decision.
The situation is, however, quite different when a range of
utility values for infertility are added to the analysis. If we
lassume utilities for peri-operative and cancer death of 0.16
and 0.106 respectively (the mean values given by our sub-
jects) and break down the analysis to include different risks
of cancer spread these results are very sensitive to changes in
the utility of infertility. Thus, when the utility of infertility is
95%, conservative therapy remains the preferred option for
all microinvasive lesions even if the chance of spread has
increased to 5% (Table IV). A utility of 0.95 implies that the
subject was prepared to lower her chances of survival by 5%
to preserve her reproductive function. When this view is felt
less strongly but nevertheless keenly, and a patient regards
life as 50 times more valuable than fertility, then a utility of
0.98 may be inferred and conservative therapy would then be
appropriate for lesions less than 3 mm, but with vascular
channel involvement and for lesions penetrating a depth of
3-5 mm with no vascular involvement. In other words the
physician must place significant weight on the patient's desire
for fertility because it has a major bearing on the choice of
treatment.
Although decision analysis has limitations conventional
intuitive decisions are also limited by a paucity of hard data.
The advantage of decision analysis is that intuitive bias is
minimised by breaking down the problem into separate com-
ponents. Despite the limitations of decision analysis and the
difficulty in measuring utility this is the best way to analyse
the question 'how should we treat women with early microin-
vasive cancer of the cervix?'
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